이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Arrowhead Pharmaceuticals 관리
관리 기준 확인 3/4
Arrowhead Pharmaceuticals' CEO는 Chris Anzalone, Dec2007 에 임명되었습니다 의 임기는 16.67 년입니다. 총 연간 보상은 $ 9.92M, 9.1% 로 구성됩니다. 9.1% 급여 및 90.9% 보너스(회사 주식 및 옵션 포함). 는 $ 84.18M 가치에 해당하는 회사 주식의 2.99% 직접 소유합니다. 84.18M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 13.8 년입니다.
주요 정보
Chris Anzalone
최고 경영자
US$9.9m
총 보상
| CEO 급여 비율 | 9.1% |
| CEO 임기 | 16.8yrs |
| CEO 소유권 | 3.0% |
| 경영진 평균 재임 기간 | 6.2yrs |
| 이사회 평균 재임 기간 | 13.8yrs |
최근 관리 업데이트
Recent updates
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12
Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
| Jun 30 2018 | n/a | n/a | -US$54m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | n/a | n/a | -US$35m |
| Sep 30 2017 | US$2m | US$616k | -US$34m |
보상 대 시장: Chris 의 총 보상 ($USD 9.92M )은 US 시장( $USD 6.84M ).
보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Chris Anzalone (55 yo)
16.8yrs
테뉴어
US$9,918,093
보상
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 16.8yrs | US$9.92m | 2.99% $ 73.1m | |
| Chief Financial Officer | 14.6yrs | US$3.12m | 0.19% $ 4.6m | |
| COO, General Counsel & Secretary | 9.8yrs | US$3.31m | 0.23% $ 5.6m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 4.0m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & VP | no data | 데이터 없음 | 데이터 없음 | |
| Director of Communications | 19.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Scientist | less than a year | US$16.34m | 데이터 없음 | |
| Head of Toxicology & VP | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 2.3yrs | US$2.97m | 0.013% $ 329.1k | |
| Head of Tax | 2.7yrs | 데이터 없음 | 데이터 없음 | |
| VP & Treasurer | 2.7yrs | 데이터 없음 | 데이터 없음 |
6.2yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: ARWR 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 16.8yrs | US$9.92m | 2.99% $ 73.1m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of the Board | 13.8yrs | US$474.60k | 0.11% $ 2.8m | |
| Independent Lead Director | 12.8yrs | US$459.60k | 0.074% $ 1.8m | |
| Independent Director | 6.7yrs | US$469.60k | 0.026% $ 646.8k | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 14.1yrs | US$459.60k | 0.037% $ 900.6k | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Hepatitis B Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 |
13.8yrs
평균 재임 기간
65yo
평균 연령
경험이 풍부한 이사회: ARWR 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.6 년).